2,573 research outputs found
GC-FID data of biocatalytic esterification reactions & NMR data of lignin characterization
No full textTabulated chromatographic data (GC-FID) from butyl butyrate esterification reactions. 13C and 31P NMR data from pine kraft lignin (BIOPIVA 100) and cationic pine kraft lignin. A list of sample code identifiers with their descriptions is available upon request from the author.<br
A Nomogram Predicting Prostate Cancer-Specific Mortality after Radical Prostatectomy
No full textObjective: We describe a model capable of predicting prostate cancer (PCa)-specific mortality up to 20 years after a radical prostatectomy (RP), which can adjust the predictions according to disease-free interval. Patients and Methods: 752 patients were treated with RP for organ-confined PCa. Cox regression modeled the probability of PCa-specific mortality. The significance of the predictors was confirmed in competing risks analyses, which account for other-cause mortality. Results: The mean follow-up was 11.4 years. The 5-, 10-, 15- and 20-year actuarial rates of PCa-specific survival were 99.0, 95.5, 90.9 and 85.7%, respectively. RP Gleason sum (p < 0.001), pT stage (p = 0.007), adjuvant radiotherapy (p = 0.03) and age at RP (p = 0.004) represented independent predictors of PCa-specific mortality in the Cox regression model as well as in competing risks regression. Those variables, along with lymph node dissection status (p = 0.4), constituted the nomogram predictors. After 200 bootstrap resamples, the nomogram achieved 82.6, 83.8, 75.0 and 76.3% accuracy in predicting PCa-specific mortality at 5, 10, 15 and 20 years post-RP, respectively. Conclusions: At 20 years, roughly 20% of men treated with RP may succumb to PCa. The current nomogram helps to identify these individuals. Their follow-up or secondary therapies may be adjusted according to nomogram predictions. Copyright (c) 2010 S. Karger AG, Base
Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin
No full textMeetresultaten Kunststof GC-elementen: Project C2: Oever- en Bodembescherming met GC
No full textAnome BV en het Innovatie Test Centrum van Rijkswaterstaat-DWW zijn samen met verschillende partners aan het onderzoeken in hoeverre Ground Consolidators (GC\u92s) interessant zouden kunnen zijn voor gebruik in Oever- en bodembescherming. De eerste fase van het onderzoek is afgerond en er is besloten om verdergaand onderzoek te doen. In verband met duurzaamheid van het materiaal, is ervoor gekozen om verder onderzoek te verrichten naar GC-elementen van kunststof. Dit onderzoek is gedaan door een drietal studenten van de TU Delft aan de faculteit Civiele Techniek. Voorliggend document bevat de meetresultaten van de kwali- en kwantitatieve experimenten die zijn uitgevoerd om de eigenschappen van kunststoffen GC\u92s en een pakket GC\u92s te bepalen
Meetresultaten Kunststof GC-elementen: Versie 4
No full textAnome BV en het Innovatie Test Centrum van Rijkswaterstaat-DWW zijn samen met verschillende partners aan het onderzoeken in hoeverre Ground Consilidators (GC\u92s) interessant zouden kunnen zijn voor gebruik in Oever- en bodembescherming. De eerste fase van het onderzoek is afgerond en er is besloten om verdergaand onderzoek te doen. In verband met duurzaamheid van het materiaal, is ervoor gekozen om verder onderzoek te verrichten naar GC-elementen van kunststof. Dit onderzoek is gedaan door een drietal studenten van de TU Delft aan de faculteit Civiele Techniek. Voorliggend document bevat de meetresultaten van de kwali- en kwantitatieve experimenten die zijn uitgevoerd om de eigenschappen van kunststoffen GC\u92s en een pakket GC\u92s te bepalen
Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study
No full textObjective: Based on the natural history of localized prostate cancer, the life expectancy (LE) of men treated with either radical prostatectomy (RP) or definitive external-beam radiotherapy (EBRT) should exceed 10 years. To test this hypothesis, we examined overall survival rates after RP or EBRT in a contemporary population-based cohort. Methods: Within a population-based cohort we assessed crude survival in 17 570 men diagnosed with prostate cancer who were either treated with RP (n = 9678) or definitive EBRT (n = 7892) between 1989 and 2000. Age and Charlson Comorbidity Index (CCI) score at treatment represented covariates. In order to control for prostate cancer-related mortality, we repeated analyses for 9131 men who did not receive any secondary treatment for prostate cancer. Results: In the entire cohort, the actuarial 10-year Survival probability after RP was 75.3%, versus 36.7% after EBRT (p < 0.001). In those who did not receive any secondary treatment, the actuarial 10-year survival probability after RP was 81.1%, versus 30.4% after EBRT (p < 0.001). In multivariate Cox regression models, EBRT was associated with a 2.8-fold (p < 0.001) and 3.9-fold (p < 0.001) higher risk of mortality in the entire cohort and in the cohort without secondary treatment, respectively. Increased CCI score and increased age were also associated with a higher risk of mortality (p < 0.001). conclusion: Some men treated with EBRT and, to a lesser extent, those treated with RP may have insufficient LE to warrant therapy with Curative intent. More stringent selection criteria are necessary to avoid overtreatment
The Private Cost of Long-Term Care in Canada: Where You Live Matters
No full textCanadians expect the same access to health care whether they are rich or poor, and wherever they live, often without direct charge at the point of service. However, we find that the private cost of long-term care differs greatly across the country, and within provinces, we find substantial variation, depending on income level, marital status, and, in Quebec alone, on assets owned. A non-married person with average income would pay more than twice as much in the Atlantic provinces as in Quebec, while a couple with one in care would pay almost four times as much in Newfoundland as in Alberta.long-term care, private cost
Validation of the Contemporary Epstein Criteria for Insignificant Prostate Cancer in European Men
No full textObjectives: The Epstein criteria represent the most widely used scheme for prediction of clinically insignificant prostate cancer (PCa). However, they were never validated in European men. We assessed the rate of unfavorable prostate cancer (Gleason 7-10 or non-organ-confined disease) in a cohort of 366 men who fulfilled the Epstein clinically insignificant PCa criteria. Methods: Between 1996 and 2006, 2580 men underwent radical prostatectomy at a single academic European institution. Of those, 366 fulfilled the contemporary Epstein clinically insignificant PCa criteria. Analyses targeted the rate of pathologically unfavorable prostate cancer, defined as either Gleason sum 7-10 or non-organ-confined disease, or a combination of these characteristics in patients with clinically insignificant PCa. Results: Gleason 7-10 prostate cancer at radical prostatectomy was found in 88 patients (24%) with clinically insignificant PCa. In addition, 30 (34.1%) of the 88 patients harboured non-organ-confined disease. Consequently, the contemporary Epstein criteria for clinically insignificant PCa were inaccurate in 24% of patients. Conclusions: The Epstein clinical insignificant PCa criteria may underestimate the true nature of prostate cancer in as many as 24% of European patients. Therefore, caution is advised when treatment decisions are based solely on these criteria. (C) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved
Meetresultaten \u93extra proef\u94 Kunststof GC-elementen: Stabiliteit, soortelijk gewicht en elasticiteit
No full textDit rapport is een aanvulling op het eindverslag van het onderzoek naar het gedrag van kunststof GC elementen voor oever- en bodembescherming. Conclusies van dat (schaal-) onderzoek waren dat een structuur van GC elementen verrassend sterke hydraulische eigenschappen bezit en daarmee interessant is als erosiebeschermer bij bodem en oeverconstructies. Beperking in het gebruik lag bij \u93stabiliteit\u94. Onder sterke stroming of golfslag was het pakket onvoldoende stabiel. Zo werden er onder zeer sterke stroming flarden uit getrokken, of bewoog het pakket enigszins onder golfslag op een talud. Er werden verschillende kunststoffen gebruikt, met verschillende soortelijke gewichten. Uit extrapolatie en precieze bestudering van het bezwijken kon verwacht worden dat gebruik van sterkere GC\u92s (minder elastisch) en zwaardere GC\u92s (stabieler) het bereik waarin de GC gebruikt kan worden aanzienlijk zou moeten kunnen vergroten
High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer
No full textObjectives: The relationship between provider volume and cancer control has not been studied in the setting of definitive radiotherapy. We examined the effect of annual and cumulative provider volume on the rate of use of secondary therapies after definitive external-beam radiotherapy (EBRT) for localized prostate cancer. Methods: The cohort consisted of 3907 patients treated with definitive radiotherapy without neoadjuvant or adjuvant hormonal therapy (delivered within 12 mo of EBRT) between 1989 and 2000. Overall median follow-up was 6.2 yr versus 3.8 yr in event-free patients. All were treated by 72 radiation oncologists, with an average annual provider volume of 14 cases (median: 10.4; range: 1-39) and an average cumulative volume of 138 (median: 105; mean: 138). Secondary treatment was defined as hormonal therapy after definitive EBRT. Age and comorbidities represented covariates in Cox regression analyses. Results: Of all patients, 731 (18.7%) received secondary therapy. The median failure-free survival was not reached (mean: 11.2 yr). At 5 and 10 yr, secondary therapy-free survival rates were 79.5% and 61.3%, respectively. Annual (p = 0.007) and cumulative (p = 0.003) provider volumes were independent predictors of failure-free survival. After adjustment for covariates, cubic splines demonstrated lower rates of secondary therapy for annual provider volume > 10 cases and for cumulative provider volume > 200 cases. Conclusions: Our data suggest that to minimize the rates of secondary therapy, EBRT should ideally be delivered by high-volume providers with an annual or cumulative volume in excess of, respectively, 10 or 200 cases. (C) 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved
- …
